Pediatr. praxi. 2011;12(2):98-101

Invasive fungal infection: application of antifungal drugs in pediatric practice

doc.MUDr.Petr Sedláček, CSc.1, MUDr.Vanda Chrenková2, MUDr.Petra Keslová3
1 Klinika dětské hematologie a onkologie, Fakultní nemocnice v Motole a 2. LF UK v Praze
2 Ústav lékařské mikrobiologie, Fakultní nemocnice v Motole, Praha
3 Klinika dětské hematologie a onkologie, Fakultní nemocnice v Motole, Praha

Invasive fungal infection (IFI) continues to be frequent cause of morbidity and mortality in neonates and in both immunocompromised

and immunocompetent children. Although these infections have been well characterized in adults, incidence, diagnostic tools, analysis

of risk factors and treatment outcomes have not been well described in children. Data regarding the efficacy, safety and proper dosing

of widely used antifungals in children of different age categories still remain to be solved. In this paper we would like to summarize news

published about this specific topic of pediatrics over year 2010 and excerpted in PubMed database.

Keywords: invasive fungal infection, antifungal agents, yeasts, koles, children

Published: April 18, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sedláček P, Chrenková V, Keslová P. Invasive fungal infection: application of antifungal drugs in pediatric practice. Pediatr. praxi. 2011;12(2):98-101.
Download citation

References

  1. Groll AH, Tragiannidis A. Update on antifungal agents for paediatric patients. Clin Microbiol Infect 2010; 16(9): 1343-1353. Go to original source... Go to PubMed...
  2. Lehrnbecher T, Frank C, Engels K, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 2010; 61(3): 259-265. Go to original source... Go to PubMed...
  3. Zaoutis T. Candidemia in children. Curr Med Res Opin 2010; 26(7): 1761-1768. Go to original source... Go to PubMed...
  4. Zaoutis TE, Prasad PA, Localio AR, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 2010; 51(5): e38-45. Go to original source... Go to PubMed...
  5. Lass-Florl C. Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy. Expert Rev Anti Infect Ther 2010; 8(2): 127-135. Go to original source... Go to PubMed...
  6. Steinbach WJ. Epidemiology of Invasive Fungal Infections in Neonates and Children. Clin Microbiol Infect 2010; 16(9): 1321-1327. Go to original source... Go to PubMed...
  7. Steinbach WJ. Invasive aspergillosis in pediatric patients. Curr Med Res Opin 2010; 26(7): 1779-1787. Go to original source... Go to PubMed...
  8. Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol 2010; 18(5): 195-204. Go to original source... Go to PubMed...
  9. Dornbusch HJ, Groll A, Walsh TJ. Diagnosis of invasive fungal infections in immunocompromised children. Clin Microbiol Infect 2010; 16(9): 1328-1334. Go to original source... Go to PubMed...
  10. Landlinger C, Preuner S, Baskova L, et al. Diagnosis of invasive fungal infections by a real-time panfungal PCR assay in immunocompromised pediatric patients. Leukemia 2010; 24(12): 2032-2038. Go to original source... Go to PubMed...
  11. Blyth CC, Hale K, Palasanthiran P, et al. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev 2010(2): CD006343. Go to original source...
  12. Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29(5): 415-420. Go to original source... Go to PubMed...
  13. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, et al. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 2010; 9(9): 719-727. Go to original source... Go to PubMed...
  14. Kobayashi R, Suzuki D, Yasuda K, Kobayashi K. Itraconazole for invasive fungal infection with pediatric malignancies. Pediatr Int 2010; 52(5): 707-710. Go to original source... Go to PubMed...
  15. Bruggemann RJ, van der Linden JW, Verweij PE, et al. Impact of Therapeutic Drug Monitoring of Voriconazole in a Pediatric Population. Pediatr Infect Dis J 2010; epub.
  16. Goutelle S, Larcher R, Padoin C, et al. Oral voriconazole dose in children: one size does not fit all. Clin Infect Dis 2010; 51(7): 870; author reply 871. Go to original source... Go to PubMed...
  17. Shima H, Miharu M, Osumi T, et al. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Cancer 2010; 54(7): 1050-1052. Go to original source... Go to PubMed...
  18. Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010; 50(1): 27-36. Go to original source... Go to PubMed...
  19. Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother 2010; 54(10): 4116-4123. Go to original source... Go to PubMed...
  20. Michael C, Bierbach U, Frenzel K, et al. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother 2010; 54(8): 3225-3232. Go to original source... Go to PubMed...
  21. Spriet I, Cosaert K, Renard M, et al. Voriconazole plasma levels in children are highly variable. Eur J Clin Microbiol Infect Dis 2010; epub. Go to original source... Go to PubMed...
  22. Vohringer S, Schrum J, Ott H, Hoger PH. Severe phototoxicity associated with long-term voriconazole treatment. J Dtsch Dermatol Ges 2010; epub. Go to original source... Go to PubMed...
  23. Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis 2010; 29(8): 1043-1045. Go to original source... Go to PubMed...
  24. VandenBussche HL, Van Loo DA. A clinical review of echinocandins in pediatric patients. Ann Pharmacother 2010; 44(1): 166-177. Go to original source... Go to PubMed...
  25. Steinbach WJ, Juvvadi PR, Fortwendel JR, Rogg LE. Newer combination antifungal therapies for invasive aspergillosis. Med Mycol 2010; epub. Go to original source... Go to PubMed...
  26. Manzoni P, Rizzollo S, Franco C, et al. Role of echinocandins in the management of fungal infections in neonates. J Matern Fetal Neonatal Med 2010; 23(Suppl. 3): 49-52. Go to original source... Go to PubMed...
  27. Benjamin DK, Jr., Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 2010; 87(1): 93-99. Go to original source... Go to PubMed...
  28. Lehrnbecher T, Groll AH. Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients. Pediatr Blood Cancer 2010; 55(2): 229-232. Go to original source... Go to PubMed...
  29. Mehta PA, Vinks AA, Filipovich A, et al. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2010; 16(10): 1458-1462. Go to original source... Go to PubMed...
  30. Kuti EL, Kuti JL. Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections. Expert Opin Drug Metab Toxicol 2010; 6(10): 1287-1300. Go to original source... Go to PubMed...
  31. Krenova Z, Pavelka Z, Lokaj P, et al. Successful treatment of life-threatening Candida peritonitis in a child with abdominal non-Hodgkin lymphoma using efungumab and amphotericin B colloid dispersion. J Pediatr Hematol Oncol 2010; 32(2): 128-130. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.